IDH1 and glioma: Over the past few years, the improvement in acquisition strategies such as 2D or, more recently 3D MRS, have resulted in the introduction of and the better understanding of the concept of the onco-metabolite evaluation of D-2 hydroxyglutarate (2-HG) in patients with IDH-mutated gliomas [113,114].